PIK3CA and non-small cell lung carcinoma: With the aim of developing effective therapeutic strategy for treatment gefitinib-resistant NSCLCs, we have initially evaluated the antitumor activity of AZD6244 alone or combination with BEZ235 in a panel of three human NSCLC cell lines, which were selected according to their different mutation status for EGFR-T790M, MET and KRAS/PIK3CA genes.